Evaluation of Diagnostic Performance of Three Indirect Enzyme-Linked Immunosorbent Assays for the Detection of IgG Antibodies to Ebola Virus in Human Sera.


Journal

Viruses
ISSN: 1999-4915
Titre abrégé: Viruses
Pays: Switzerland
ID NLM: 101509722

Informations de publication

Date de publication:
24 07 2019
Historique:
received: 29 05 2019
revised: 10 07 2019
accepted: 11 07 2019
entrez: 27 7 2019
pubmed: 28 7 2019
medline: 26 9 2020
Statut: epublish

Résumé

Filovirus serological diagnosis and epidemiological investigations are hampered due to the unavailability of validated immunoassays. Diagnostic performance of three indirect enzyme-linked immunosorbent assays (I-ELISA) was evaluated for the detection of IgG antibody to Ebola virus (EBOV) in human sera. One I-ELISA was based on a whole EBOV antigen (WAg) and two utilized recombinant nucleocapsid (NP) and glycoproteins (GP), respectively. Validation data sets derived from individual sera collected in South Africa (SA), representing an EBOV non-endemic country, and from sera collected during an Ebola disease (EBOD) outbreak in Sierra Leone (SL), were categorized according to the compounded results of the three I-ELISAs and real time reverse-transcription polymerase chain reaction (RT-PCR). At the cut-off values selected at 95% accuracy level by the two-graph receiver operating characteristic analysis, specificity in the SA EBOV negative serum panel (

Identifiants

pubmed: 31344850
pii: v11080678
doi: 10.3390/v11080678
pmc: PMC6722596
pii:
doi:

Substances chimiques

Antibodies, Viral 0
Antigens, Viral 0
Glycoproteins 0
Immunoglobulin G 0
Nucleocapsid Proteins 0
nucleocapsid protein, Ebola virus 0

Types de publication

Evaluation Study Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Références

J Immunol Methods. 1996 May 10;191(1):93-4
pubmed: 8642206
Virol Sin. 2014 Dec;29(6):372-80
pubmed: 25547682
J Immunol Methods. 1995 Sep 11;185(1):145-6
pubmed: 7665897
Nat Rev Microbiol. 2019 May;17(5):261-263
pubmed: 30926957
Vaccine. 2007 Jan 22;25(6):993-9
pubmed: 17055127
J Virol Methods. 2005 Mar;124(1-2):173-81
pubmed: 15664066
Microbes Infect. 2003 Apr;5(5):379-85
pubmed: 12737993
J Gen Virol. 1998 Nov;79 ( Pt 11):2565-72
pubmed: 9820131
Prev Vet Med. 2000 May 30;45(1-2):43-59
pubmed: 10802333
Lancet Glob Health. 2015 Aug;3(8):e439-e440
pubmed: 26163833
PLoS One. 2019 Apr 18;14(4):e0215457
pubmed: 30998735
Clin Vaccine Immunol. 2012 Nov;19(11):1844-52
pubmed: 22993411
Clin Vaccine Immunol. 2016 Aug 05;23(8):717-24
pubmed: 27335383
PLoS One. 2019 Mar 7;14(3):e0212113
pubmed: 30845203
Rev Sci Tech. 1993 Jun;12(2):435-50
pubmed: 8400384
J Infect Dis. 2016 Oct 15;214(suppl 3):S222-S228
pubmed: 27443616
Clin Vaccine Immunol. 2010 Nov;17(11):1723-8
pubmed: 20861331
N Engl J Med. 2014 Oct 9;371(15):1418-25
pubmed: 24738640
J Infect Dis. 2007 Nov 15;196 Suppl 2:S199-204
pubmed: 17940950
PLoS Negl Trop Dis. 2011 Jun;5(6):e1175
pubmed: 21666792
J Infect Dis. 1999 Feb;179 Suppl 1:S28-35
pubmed: 9988162
Front Microbiol. 2014 Apr 17;5:172
pubmed: 24860555
J Infect Dis. 1999 Feb;179 Suppl 1:S177-87
pubmed: 9988182
Methods Mol Biol. 1995;42:1-218
pubmed: 7655571
Lancet. 2015 May 9;385(9980):1902-9
pubmed: 25987158
J Clin Microbiol. 1984 Sep;20(3):486-9
pubmed: 6490832
Virus Res. 1993 Sep;29(3):215-40
pubmed: 8237108
Clin Diagn Lab Immunol. 2003 Jan;10(1):83-7
pubmed: 12522044
Lancet Infect Dis. 2019 May;19(5):529-536
pubmed: 30928435
N Engl J Med. 2014 Sep 25;371(13):1180-3
pubmed: 25140855
Methods Mol Biol. 2017;1628:353-362
pubmed: 28573634
Emerg Infect Dis. 2016 Jul;22(7):1292-4
pubmed: 27070504
Virol Sin. 2018 Aug;33(4):323-334
pubmed: 30066045
Antiviral Res. 2016 Feb;126:55-61
pubmed: 26681387
Lancet Infect Dis. 2017 Jun;17(6):645-653
pubmed: 28256310
N Engl J Med. 2014 Oct 16;371(16):1481-95
pubmed: 25244186
J Clin Microbiol. 2001 Jan;39(1):1-7
pubmed: 11136739
PLoS Negl Trop Dis. 2017 Jun 19;11(6):e0005665
pubmed: 28628619
J Clin Microbiol. 2016 Feb;54(2):359-67
pubmed: 26637383
PLoS Negl Trop Dis. 2018 Jan 5;12(1):e0006135
pubmed: 29304039
J Infect Dis. 1999 Feb;179 Suppl 1:S192-8
pubmed: 9988184
J Vet Diagn Invest. 2009 Sep;21(5):598-608
pubmed: 19737754
Emerg Infect Dis. 2009 Jul;15(7):1136-7
pubmed: 19624943
Med Microbiol Immunol. 2016 Apr;205(2):173-83
pubmed: 26475282
Viruses. 2012 Dec 06;4(12):3511-30
pubmed: 23223188
Global Health. 2017 Jan 4;13(1):1
pubmed: 28049495
Biometrics. 1977 Mar;33(1):159-74
pubmed: 843571
Onderstepoort J Vet Res. 2012 Jun 20;79(2):451
pubmed: 23327370
Curr Opin Biotechnol. 1998 Oct;9(5):528-33
pubmed: 9821284
Crit Care Med. 2000 Jan;28(1):240-4
pubmed: 10667531
Rev Sci Tech. 1998 Aug;17(2):469-526
pubmed: 9713892
Lancet. 2019 Feb 16;393(10172):617-620
pubmed: 30732850

Auteurs

Janusz T Paweska (JT)

Centre for Emerging Zoonotic and Parasitic Diseases, National Institute for Communicable Diseases of the National Health Laboratory Service, Sandringham, Johannesburg 2131, South Africa. januszp@nicd.ac.za.
Faculty of Health Sciences, University of the Witwatersrand, Johannesburg 2050, South Africa. januszp@nicd.ac.za.

Naazneen Moolla (N)

Centre for Emerging Zoonotic and Parasitic Diseases, National Institute for Communicable Diseases of the National Health Laboratory Service, Sandringham, Johannesburg 2131, South Africa.

Nadia Storm (N)

Centre for Emerging Zoonotic and Parasitic Diseases, National Institute for Communicable Diseases of the National Health Laboratory Service, Sandringham, Johannesburg 2131, South Africa.

Veerle Msimang (V)

Centre for Emerging Zoonotic and Parasitic Diseases, National Institute for Communicable Diseases of the National Health Laboratory Service, Sandringham, Johannesburg 2131, South Africa.

Ousman Conteh (O)

Ministry of Health and Sanitation, Freetown 47235, Sierra Leone.

Jacqueline Weyer (J)

Centre for Emerging Zoonotic and Parasitic Diseases, National Institute for Communicable Diseases of the National Health Laboratory Service, Sandringham, Johannesburg 2131, South Africa.

Petrus Jansen van Vuren (PJV)

Centre for Emerging Zoonotic and Parasitic Diseases, National Institute for Communicable Diseases of the National Health Laboratory Service, Sandringham, Johannesburg 2131, South Africa.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH